|
|
|
|
|||||
|
|
|
New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.
Mettler-Toledo International MTD reported fourth-quarter 2025 adjusted earnings of $13.36 per share, which beat the Zacks Consensus Estimate by 4.67%. The bottom line increased 8% on a year-over-year basis.
Net sales of $1.13 billion surpassed the Zacks Consensus Estimate by 2.53%. The figure increased 8% on a reported basis and 5% on a local currency basis from the year-ago quarter.
MTD reported revenues under three segments, namely Laboratory, Industrial and Food Retail, which generated sales of $638 million (56.5% of the net sales), $437 million (38.7% of the net sales) and $54 million (4.8% of the net sales), respectively, in the fourth quarter. The Laboratory, Industrial, and Food Retail segments witnessed year-over-year growth of 3%, 7% and 19%, respectively, on a local currency basis.
Total sales from the Americas, Europe and Asia/Rest of the World were $456 million (40.4% of the net sales), $346 million (30.6%) and $328 million (29.1%), respectively. Sales in the Americas, Europe and Asia / Rest of the World increased 7%, 4% and 4% year over year, respectively, on a local currency basis.
Mettler-Toledo International, Inc. price-consensus-eps-surprise-chart | Mettler-Tole Mettler-Toledo’s Q4 Operating Details
In the fourth quarter of 2025, the gross margin was 59.8%, which contracted 140 basis points (bps) year over year.
Research & development (R&D) expenses were $52.6 million, up 5.1% year over year. Selling, general & administrative (SG&A) expenses increased 9.5% year over year to $259.8 million. As a percentage of sales, R&D expenses decreased 10 bps year over year. SG&A expenses increased 30 bps year over year as a percentage of sales.
The adjusted operating margin was 32.2%, which declined 150 bps year over year.
As of Dec. 31, 2025, Mettler-Toledo’s cash and cash-equivalent balance was $66.9 million, down from $69.1 million as of Sept. 30. The long-term debt was $2.09 billion as of Sept. 30, 2025.
Mettler-Toledo generated $225.6 million in cash from operating activities in the reported quarter. The free cash flow was $188.1 million in the reported quarter.
For the first quarter of 2026, Mettler-Toledo anticipates sales to increase roughly 3% in local currency year over year.
Adjusted earnings are anticipated to be between $8.60 per share and $8.75 per share, a growth rate of 5% to 7% year over year.
For 2026, Mettler-Toledo anticipates sales in local currency to increase approximately 4% over 2024. The company expects adjusted earnings between $46.05 per share and $46.70 per share, representing 8-9% growth over 2025.
Currently, Mettler-Toledo carries a Zacks Rank #3 (Hold).
Actuate Therapeutics ACTU, Alkermes ALKS and Amneal Pharmaceuticals AMRX are some better-ranked stocks that investors can consider in the broader Zacks Medical sector.
Actuate Therapeutics shares have dropped 49.2% in the trailing 12-month period. The company is scheduled to release fourth-quarter 2025 results on Mar. 12. ACTU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alkermes shares have returned 9.8% in the trailing 12-month period. ALKS is scheduled to release fourth-quarter 2025 results on Feb. 11. Alkermes sports a Zacks Rank #1.
Amneal Pharmaceuticals has returned 87.1% in the trailing 12-month period. AMRX is set to report its fourth-quarter 2025 results on Feb. 27. The company currently carries a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 8 min | |
| 1 hour | |
| 2 hours | |
| 4 hours | |
| 4 hours | |
| Feb-05 | |
| Feb-05 | |
| Feb-05 | |
| Feb-05 | |
| Feb-05 | |
| Feb-05 | |
| Feb-05 | |
| Feb-04 | |
| Feb-04 | |
| Feb-04 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite